SHANGHAI – Clinical-stage immuno-oncology company, Beigene Co. Ltd., of Beijing, has announced its intention to raise $100 million on Nasdaq. A member of the small but growing group of rising biotech stars in China, Beigene filed IPO intentions to sell American depository shares with the SEC as an emerging growth company with reduced filing requirements. Pricing terms were undisclosed. Read More

HONG KONG – Another China-based company has filed for a $100 million IPO on Nasdaq, testing what has been a friendly environment for biotech. Hutchison China Meditech Ltd. hasn't decided on the timeline of the listing, nor the number and price of shares. The proposed maximum offering price is $100 million. Read More

SHANGHAI – Hutchison Medipharma Ltd., a Shanghai-based drug R&D subsidiary of Hutchison China Meditech, with its partner Astrazeneca plc, enrolled 90 patients at 22 sites in a global phase II trial for savolitinib (AZD6094) in papillary renal cell carcinoma (PRCC), a type of cancer that afflicts 48,000 people annually, or about 14 percent of new cases of kidney cancer in the world. Read More

NEW DELHI – Claiming that the unregulated proliferation of online sales of pharmaceuticals in India could put lives at risk and threaten their businesses, some 800,000 pharmacies shut down for a day on Oct. 14. Online sales have been in the spotlight in recent months after the government sought out public input on how best to regulate the practice. Read More

HONG KONG — A new Chinese study showing that enhancement of the natural generation of new neurons using a biodegradable material that allows the gradual release of a neurotrophic agent could represent a novel strategy for treating spinal cord injuries (SCI). Clinical trials of the approach may be imminent. Read More

HONG KONG – After being granted phase II trial approval in Sierra Leone last Saturday for its novel Ebola vaccine, Tianjin Cansino Biotechnology Inc. became the first Chinese vaccine company with a self-developed vaccine approved for clinical trials in a foreign country. Read More

Lupin Ltd., of Mumbai, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, said they inked an alliance to co-market Boehringer's linagliptin, a DPP-4 inhibitor, in India. Under the terms, Lupin will market and sell the drug under the brand Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin), using its 400-strong diabetes specialty field force. Read More